glp 1 agonist novo nordisk Ozempic maker is working on a once-monthly weight-loss drug GLP-1s for Alzheimer's: Novo Nordisk

Leana Wen explains what people should know about the medication.

Evidence is emerging that glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and chondroprotective properties independent of their effects on weight loss

Scientists have now created long-lasting GLP-1 drugs that can be used to treat type 2 diabetes, obesity, and a range of other conditions

For the 40% of American adults with obesity, glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, may offer hopebut the cost can put them out of reach for many patients

Tirzepatide, sold under the name Mounjaro, is among a handful of drugs with big buzz for their weight loss results, and approval for obesity could be a huge revenue source for Eli Lilly in the future.

Additionally, we highlight the gaps for further studies in clinical applications of GLP-1 RAs in aging-related diseases